AbbVie Inc (NYSE: ABBV) reported Q3 adjusted EPS of $3.66, up 29.3% Y/Y and beating the consensus of $3.59.
Overall sales increased 3.3% Y/Y (5.4% on an operational basis) to $14.81 billion, missing the consensus of $14.96 billion.
The immunology portfolio generated $7.65 billion in sales, +14.6% (+16.4% on an operational basis). Humira sales increased 2.5% to $5.56 billion. Skyrizi sales reached $1.39 billion (+75.4% Y/Y), and Rinvoq jumped 53.5% to $695 million.
Hematologic oncology portfolio sales were $1.65 billion, down 11.7% (-9.9% on an operational basis). Imbruvica sales decreased 17.4% to $1.34 billion. Venclexta revenues were up 4.5% to $515 million.
Sales from the neuroscience portfolio reached $1.67 billion, +6.7%. Aesthetics portfolio sales increased 4% (+8.1% on an operational basis) to $1.30 billion, with $637 million in Botox sales for cosmetic uses.
Dividend: AbbVie increased the quarterly dividend by 5% from $1.41 per share to $1.48 per share.
Guidance: AbbVie confirms FY22 adjusted EPS guidance and narrows the range from $13.76 - $13.96 to $13.84 - $13.88, compared to the consensus of $13.86.
Price Action: ABBV shares are up 0.71% at $150.89 during the premarket session on the last check Friday.
See more from Benzinga
Alpine Immune Sciences Stops Davoceticept Trials In Cancer Indications After Second Patient Death
Former NFL QB Colin Kaepernick The Latest SPAC Casualty, Costing Investors Millions - Mission Advancement
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
